ANI 制药

最新新闻

• 评级变动
  Truist Financial Maintains ANI Pharmaceuticals(ANIP.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/5/11
• 评级变动
  J.P. Morgan Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Maintains Target Price $115
  \u5e02\u573a\u8d44\u8baf · 2026/8/10
• Barclays Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Maintains Target Price $100
  \u5e02\u573a\u8d44\u8baf · 2026/8/26
• H.C. Wainwright Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Maintains Target Price $121
  \u5e02\u573a\u8d44\u8baf · 2026/9/22
• Leerink Partners Initiates ANI Pharmaceuticals(ANIP.US) With Buy Rating, Announces Target Price $104
  \u5e02\u573a\u8d44\u8baf · 2026/9/9
• 评级变动
  Guggenheim Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Raises Target Price to $115
  \u5e02\u573a\u8d44\u8baf · 2025/11/10
• 评级变动
  Truist Financial Downgrades ANI Pharmaceuticals(ANIP.US) to Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2025/11/10
• 评级变动
  CCORF Maintains ANI Pharmaceuticals(ANIP.US) With Hold Rating, Maintains Target Price $91
  \u5e02\u573a\u8d44\u8baf · 2026/7/17
• 评级变动
  J.P. Morgan Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Raises Target Price to $115
  \u5e02\u573a\u8d44\u8baf · 2025/9/24
• 评级变动
  Guggenheim Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Maintains Target Price $115
  \u5e02\u573a\u8d44\u8baf · 2026/1/13
• 评级变动
  Guggenheim Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Maintains Target Price $124
  \u5e02\u573a\u8d44\u8baf · 2026/7/14
• Guggenheim Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Cuts Target Price to $119
  \u5e02\u573a\u8d44\u8baf · 2026/8/10
• CCORF Maintains ANI Pharmaceuticals(ANIP.US) With Hold Rating, Cuts Target Price to $90
  \u5e02\u573a\u8d44\u8baf · 2026/8/10
• 评级变动
  Guggenheim Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Maintains Target Price $114
  \u5e02\u573a\u8d44\u8baf · 2025/10/28
• 评级变动
  Piper Sandler Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Raises Target Price to $111
  \u5e02\u573a\u8d44\u8baf · 2026/4/23
• 评级变动
  Leerink Partners Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Raises Target Price to $103
  \u5e02\u573a\u8d44\u8baf · 2025/10/15
• 评级变动
  CCORF Downgrades ANI Pharmaceuticals(ANIP.US) to Hold Rating, Raises Target Price to $91
  \u5e02\u573a\u8d44\u8baf · 2026/7/17
• 评级变动
  Jefferies Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Raises Target Price to $120
  \u5e02\u573a\u8d44\u8baf · 2026/3/25
• 评级变动
  Guggenheim Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Raises Target Price to $124
  \u5e02\u573a\u8d44\u8baf · 2026/1/16
• 评级变动
  H.C. Wainwright Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Raises Target Price to $121
  \u5e02\u573a\u8d44\u8baf · 2025/9/17

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。